Clinical trials: Human Immunodeficiency Virus (HIV) Infection
Human Immunodeficiency Virus (HIV) Infection
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to <12 years and weighing <45 kg, who are treatment-naive (TN) or have been…
- Trial name
- NCT04375800
- Testing
- Doravirine, 2 NRTIs, DOR/3TC/TDF
- Where
- 26 sites in United States, Colombia and 6 more
- Volunteers
- 84 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in…
- Trial name
- NCT07266831
- Testing
- ISL, ULO, BIC/FTC/TAF
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
Tuberculosis (TB), Tuberculosis Infection, Latent
Screening With Portable X-rays for Rapid Recognition of TB
SPOT-TB (Screening with Portable X-rays for rapid recOgniTion of TB) is a prospective study evaluating a community-based tuberculosis (TB) screening strategy for migrant populations in New York City.
- Conditions
- Tuberculosis (TB), Tuberculosis Infection, Latent, HIV (Human Immunodeficiency Virus)
- Trial name
- SPOT-TB (NCT07737275)
- Testing
- Mobile chest radiography for tuberculosis screening
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Human Immunodeficiency Virus Infection (HIV)
Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIV
Infection with the human immunodeficiency virus (HIV) is a chronic condition requiring lifelong antiretroviral therapy (ART). Despite prolonged virological control under suppressive ART, HIV persists in the form of a stable viral…
- Trial name
- INSTINCT-HIV (NCT07849933)
- Testing
- Blood test
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
HIV -1 Infection, HIV (Human Immunodeficiency Virus)
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment.
- Conditions
- HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
- Trial name
- REINITIATE (NCT07476339)
- Testing
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- CAN Community Health
HPV Associated Cancers, HIV (Human Immunodeficiency Virus)
CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
This study is testing the immunotherapeutic agent, PDS0101, in adults living with HIV who are also infected with human papillomavirus (HPV) type 16.
- Conditions
- HPV Associated Cancers, HIV (Human Immunodeficiency Virus), Anal Cancer, Cervical Cancer
- Trial name
- NCT07090174
- Testing
- PDS0101
- Where
- 3 sites in United States, Puerto Rico
- Sponsor
- University of California, San Diego
Human Immunodeficiency Virus (HIV) Infection
Bioequivalence Study of ADC118 Tablets in Healthy Chinese Volunteers Under Fasting Conditions
This clinical trial aims to evaluate the bioequivalence of a single oral dose of the test drug ADC118 tablets compared with the reference drugs (ACC017 tablets and emtricitabine/tenofovir alafenamide fumarate tablets [II]) under…
- Trial name
- NCT07753902
- Testing
- ACC118-Test, Reference
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Cervical Cancer, Human Papillomavirus (HPV) Infection
Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually.
- Conditions
- Cervical Cancer, Human Papillomavirus (HPV) Infection, Human Immunodeficiency Virus (HIV) Infection
- Trial name
- SAKHI (NCT07209917)
- Testing
- SAKHI HPV Intervention, Enhanced Standard of Care (SOC+)
- Where
- 4 sites in India
- Volunteers
- 348 people
- Sponsor
- University of California, Irvine
HIV-1-infection, Human Immunodeficiency Virus
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
- Conditions
- HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
- Trial name
- NCT03729778
- Testing
- Prevnar-13
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- VA Eastern Colorado Health Care System
Menopausal Complaints, Vaginal Atrophy
Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV
This is a research study about the effects of vaginal estradiol compared to moisturizer on vaginal symptoms of menopause and the microbiome in women with HIV.
- Conditions
- Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus)
- Trial name
- NCT07526948
- Testing
- Vaginal estradiol tablets, Vaginal moisturizer
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Human Immunodeficiency Virus Infection (HIV), HIV-1 Infection in Adults
Long-Term Real-World Evidence Study to Evaluate Effectiveness, Persistence, Adherence, Safety and Tolerability of Long-acting Cabotegravir Plus Rilpivirine.
The RELATIVITY study is a nationwide, multicenter, ambispective observational cohort evaluating the long-term effectiveness, safety, persistence, and tolerability of long-acting injectable cabotegravir plus rilpivirine (CAB+RPV…
- Trial name
- NCT07703748
- Where
- Spain
- Volunteers
- 3,346 people
- Sponsor
- FUNDACIÓN HOSPITAL UNIVERSITARIO INFANTA LEONOR Y DEL HOSPITAL UNIVERSITARIO DEL SURESTE
Infection, Human Immunodeficiency Virus, HIV Infections
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2…
- Trial name
- NCT02951052
- Testing
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA)
- Where
- 113 sites in United States, Argentina and 11 more
- Volunteers
- 618 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection
Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study
This study evaluates the real-world effectiveness and safety of a long-acting injectable HIV treatment consisting of cabotegravir and rilpivirine in people living with HIV-1.
- Conditions
- Human Immunodeficiency Virus (HIV)-1 Infection, HIV-1 Subtype A6 Infection, HIV-1 Subtype B Infection, Virologically Suppressed HIV-1 Infection Receiving Long-Acting Antiretroviral Therapy
- Trial name
- LACRIS (NCT07370649)
- Testing
- Cabotegravir Plus Rilpivirine Long-Acting Injectable
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 250 people
- Sponsor
- Pomeranian Medical University Szczecin
Human Immunodeficiency Virus, Alcohol-Related Disorders
Project Khanya: Peer-Delivered Intervention to Improve HIV Medication Adherence and Substance Use in South Africa
The purpose of this study is to evaluate a stepped care behavioral intervention for HIV medication adherence and substance use ("Khanya") integrated into an HIV primary care setting in South Africa.
- Conditions
- Human Immunodeficiency Virus, Alcohol-Related Disorders, Drug Use, Substance Use
- Trial name
- NCT05933226
- Testing
- Khanya
- Where
- South Africa
- Volunteers
- 160 people
- Sponsor
- University of Maryland, College Park
Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection
Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System
The goal of this observational study is to develop, implement, and evaluate a machine learning algorithm-based Hepatitis C Emergency Department (HepC-EnD) screening tool for use in emergency departments (EDs) to identify patients…
- Conditions
- Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection, HIV (Human Immunodeficiency Virus)
- Trial name
- HepC-EnD (NCT07406490)
- Testing
- Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening)
- Where
- 3 sites in United States
- Volunteers
- 6,466 people, healthy volunteers welcome
- Sponsor
- University of Florida
HIV (Human Immunodeficiency Virus), Chlamydia
Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland
The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young…
- Conditions
- HIV (Human Immunodeficiency Virus), Chlamydia, Gonorrhea, Syphilis
- Trial name
- feSTI (NCT07516912)
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Human Immunodeficiency Virus (HIV) Infection
Strategies to AchieVe Viral Suppression for Youth With HIV
Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression (VS), when compared to other…
- Trial name
- SAVVY (NCT06886971)
- Testing
- The SAVVY intervention includes CHOICE counseling and shared decision-making regarding ART preference (informed by the evidence-based HIV-ASSIST) and facilitating LA-ART access
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Johns Hopkins University
HIV (Human Immunodeficiency Virus), HIV -1 Infection
Combining Latency Reversing Agents to Address the HIV Reservoir
The PLUTO trial aims to contribute to the worldwide search for a functional cure of HIV. One the strategies ("shock and kill' strategy) aims to reverse the HIV-reservoir from latency by increasing cell-associated HIV-RNA, which…
- Trial name
- PLUTO (NCT07384624)
- Testing
- Pyrimethamine (PYR), Lenalidomide, Topiramate (drug)
- Where
- 4 sites in Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
HIV Infections, Gender Identity
Trans People Living With HIV Throughout Europe
The project will study a European cohort of individuals identifying themselves as transgender or non-binary and living with HIV.
- Conditions
- HIV Infections, Gender Identity, Human Immunodeficiency Virus
- Trial name
- TIME (NCT03922269)
- Where
- 4 sites in Italy, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Human Immunodeficiency Virus (HIV) Infection
Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART
This is a study of HB-502 and HB-501 alternating 2-vector therapy in people living with human immunodeficiency virus (HIV) who are taking antiretroviral treatment (ART).
- Trial name
- NCT06430905
- Testing
- HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Hookipa Biotech GmbH